Myeloma survival statistics

Coronavirus (COVID-19)

We have created a central resources hub for Health Professionals which hosts all of our CRUK resources and further materials to help with managing the pandemic. We are updating the information as guidance changes. There is also a page specifically for patients on our about cancer hub.

Health Professional COVID-19 and Cancer Hub

Survival

Survive myeloma for 10 or more years, 2013-2017, England

Age

Age that myeloma survival is highest, 2009-2013, England

 

Improvement

Myeloma survival in the UK has quadrupled in the last 40 years

 

83.1% of males survive myeloma for at least one year. This falls to 52.6% surviving for five years or more, as shown by age-standardised net survival for patients diagnosed with myeloma during 2013-2017 in England.[1] Survival for females at one year is 82.1% and falls to 51.8% surviving for at least five years. Survival for females is similar to than for males at one year, and similar to at five years.

Myeloma Age-Standardised One-, Five- and Ten-Year Net Survival, Adults (Aged 15-99), England, 2013-2017

The bar chart shows one- and five-year net survival and predicted ten-year net survival, with 95% confidence intervals. Open a glossary item
 

Myeloma survival continues to fall beyond five years after diagnosis. 28.8% of males and 29.5% of females are predicted to survive their disease for ten years or more, as shown by age-standardised net survival for patients diagnosed with myeloma during 2013-2017 in England.[1]

References

  1. Office for National Statistics, Cancer survival by stage at diagnosis for England, 2019.

About this data

Data is for England, 2013 - 2017, ICD-10 C67.

Survival statistics give an overall picture of survival and the survival time experienced by an individual patient may be much higher or lower, depending on specific patient and tumour characteristics.

Last reviewed:

Five-year survival for myeloma decreases with increasing age. Five-year net survival in men ranges from 74% in 15-49 year-olds to 24% in 80-99 year-olds for patients diagnosed with myeloma in England during 2009-2013.[1] In women, five-year survival ranges from 74% to 26% in the same age groups.

Older myeloma patients may be in poorer general health, so considered ineligible for transplants and unable to tolerate strong or sustained chemotherapy, which may explain their lower survival.[2,3]

Myeloma (C90), Five-Year Net Survival by Age, England, 2009-2013

Last reviewed:

As with most cancers, survival for myeloma is improving. Some of the increase is likely to be attributable to earlier diagnosis and better detection,[1] though improvements since the early 1990s probably reflect the effective and widespread use of high-dose chemotherapy and autologous stem cell transplantation from the mid-1980s onwards.

One-year age-standardised Open a glossary item net survival for myeloma in men has increased from 37% during 1971-1972 to 78% during 2010-2011 in England and Wales – an absolute survival difference Open a glossary item of 41 percentage points.[2] In women, one-year survival has increased from 38% to 75% over the same time period (a difference of 37 percentage points).

Myeloma (C90), Age-Standardised One-Year Net Survival, Adults (Aged 15-99), England and Wales, 1971-2011

Five-year age-standardised net survival for myeloma in men has increased from 12% during 1971-1972 to a predicted survival of 50% during 2010-2011 in England and Wales – an absolute survival difference of 38 percentage point.[2] In women, five-year survival has increased from 11% to 44% over the same time period (a difference of 32 percentage points).

Myeloma (C90), Age-Standardised Five-Year Net Survival, Adults (Aged 15-99), England and Wales, 1971-2011

Five-year survival for 2010-2011 is predicted using an excess hazard statistical model

Ten-year survival has increased by a lesser amount than one- and five-year survival since the early 1970s. Ten-year age-standardised net survival for myeloma in men has increased from 7% during 1971-1972 to a predicted survival of 37% during 2010-2011 in England and Wales – an absolute survival difference of 29 percentage points.[2] In women, ten-year survival has increased from 6% to 28% over the same time period (a difference of 23 percentage points). Overall, a third of people diagnosed with myeloma today are predicted to survive their disease for at least ten years.

Myeloma (C90), Age-Standardised Ten-Year Net Survival, Adults (Aged 15-99), England and Wales, 1971-2011

Ten-year survival for 2005-2006 and 2010-2011 is predicted using an excess hazard statistical model

Myeloma survivors may experience long-term consequences of their disease and side effects of the treatments they receive for it, including peripheral neuropathy, blood clots and gastrointestinal problems.[3] Accordingly, as survival rates improve, supportive care will play an increasingly vital role in myeloma management.

References

  1. Renshaw C, Ketley N, Møller H, et al. Trends in the  incidence and survival of multiple myeloma in South East England 1985-2004.  BMC Cancer 2010;10:74.
  2. Data were provided by London School of Hygiene and Tropical  Medicine on request, 2014.
  3. Snowden JA, Ahmedzai SH, Ashcroft J, et al. Guidelines for  supportive care in multiple myeloma 2011. Brit J Haematol  2011;154(1):76-103.

About this data

Data is for: England and Wales, 1971-2011, ICD-10 C90

Last reviewed:

Survival for myeloma is strongly related to stage of the disease at diagnosis.

One-year net survival by stage 

One-year net survival for myeloma is highest for patients diagnosed at Stage 1, and lowest for those diagnosed at Stage 3 (data for Stage 4 is not available), as 2013-2017 data for England show.[1] 96% of patients diagnosed at Stage 1 survived their disease for at least one year, compared to 80% of patients diagnosed at Stage 3.[1]

One year net survival for unknown or missing stage is 81%, while one year survival for unstageable cancer is 83%. Lack of staging information may in some cases reflect advanced stage at diagnosis as very unwell patients may not undergo staging tests if the invasiveness of the testing outweighs the potential benefit of obtaining stage information. Incomplete staging assessment may also be associated with socio-demographic and clinical characteristics of the patient [2]. Stage completeness for myeloma was 28% in 2013-2017 [1].

There are no differences in survival between females and males for any of the available stages.

Myeloma cancer one-year net survival by stage, with incidence by stage (all data: adults diagnosed 2013-2017, followed up to 2018)

 

References

  1. Office for National Statistics, Cancer survival by stage at diagnosis for England , 2019. 

  2. Girolamo, C. et al, Characteristics of patients with missing information on stage: a population-based study of patients diagnosed with a colon, lung or breast cancer in England in 2013, BMC Cancer (2018) 18:492

About this data 

Data is for: England, 2013 - 2017, ICD-10 C90.  

Survival statistics give an overall picture of survival but the survival time experienced by an individual patient may be much higher or lower, depending on specific patient and tumour characteristics.

Last reviewed:

The most recent England-wide data for 2004-2006 showed three-year survival rates were significantly lower in the most deprived areas than in the most affluent (41.1% versus 49.4% for men, 39.6% versus 47.5% for women).[1] However, a similar study from Scotland for 1996-2000 did not find any differences in survival by deprivation.[2]

References

  1. Rachet B, Ellis L, Maringe C, et al. Socioeconomic inequalities in cancer survival in England after the NHS cancer plan. Brit J Cancer 2010;103(4):446-53. 
  2. Shack LG, Rachet B, Brewster DH, et al. Socioeconomic inequalities in cancer survival in Scotland 1986–2000. Brit J Cancer 2007;97(7):999-1004.

About this data

See source for ICD codes and other data specifics

Last reviewed:

The most recent five-year survival data for 1995-1999 show England is slightly below the average for Europe, while Scotland, Wales and Northern Ireland are around the European average.[1] Across the European countries, five-year survival rates range from 23.1% to 46.7%. However, as with international incidence estimates, differing data collection practices throughout Europe may contribute to the ranking of individual countries.

Last reviewed:

Cancer stats explained

See information and explanations on terminology used for statistics and reporting of cancer, and the methods used to calculate some of our statistics.

Citation

You are welcome to reuse this Cancer Research UK content for your own work.
Credit us as authors by referencing Cancer Research UK as the primary source. Suggested styles are:

Web content: Cancer Research UK, full URL of the page, Accessed [month] [year].
Publications: Cancer Research UK ([year of publication]), Name of publication, Cancer Research UK.
Graphics (when reused unaltered): Credit: Cancer Research UK.
Graphics (when recreated with differences): Based on a graphic created by Cancer Research UK.

When Cancer Research UK material is used for commercial reasons, we encourage a donation to our life-saving research.
Send a cheque payable to Cancer Research UK to: Cancer Research UK, 2 Redman Place, London, E20 1JQ or

Donate online

We’re now on twitter.
Join the conversation and follow @CRUKHCPs for news, updates and opinion.

@CRUKHCPs

Acknowledgements

We are grateful to the many organisations across the UK which collect, analyse, and share the data which we use, and to the patients and public who consent for their data to be used. Find out more about the sources which are essential for our statistics.